The purpose of this article is to provide a comprehensive review of wheezing in sickle cell disease (SCD), including epidemiology, pathophysiology, associations between wheezing and SCD morbidity and finally the clinical approach to evaluation and management of individuals with SCD who wheeze.
INTRODUCTION
Wheezing is defined by the American Thoracic Society as high-pitched continuous adventitial lung sounds, presumed to be caused by turbulent air flow through narrowed small and medium size airways in the lung [1] . Although wheeze is a symptom most closely associated with a diagnosis of asthma, there are many other causes; and for individuals with sickle cell disease (SCD), emerging data suggest that wheezing may be a pulmonary manifestation of SCD. The purpose of this article is to provide a comprehensive review of wheezing in SCD, including epidemiology, pathophysiology, associations between wheezing and SCD morbidity and finally the clinical approach to evaluation and management of individuals with SCD who wheeze.
SCD is an inherited disorder of hemoglobin that affects approximately 100 000 Americans [2] . SCD follows an autosomal recessive inheritance pattern and refers to a family of genetic mutations that affect the beta globin gene. The most common mutation in SCD involves substitution of glutamine for valine at codon six of the beta globin gene. Instead of wild type hemoglobin (referred to as hemoglobin A), this mutation produces hemoglobin S, which forms rigid polymers under deoxygenated conditions (thus giving red cells their characteristic sickled shape). Individuals who are homozygous for this mutation have hemoglobin SS (widely referred to as sickle cell anemia); however, a number of other mutations of beta globin have been described. The umbrella term 'sickle cell disease' refers to genotypes in which both beta globin genes carry a mutation, at least one of which is hemoglobin S. For individuals living with the disease, the lung is the only organ capable of reversing the polymerization of hemoglobin and decreasing the proportion of red blood cells that are sickled, the cells that initiate vascular injury and the cascade of systemic complications. Thus, any pulmonary disease occurring in SCD would be expected to significantly compromise individuals with SCD because of attenuated ability to reverse red blood cell polymerization.
Clinical and preclinical data strongly suggest that lung disease increases SCD-morbidity and mortality. More specifically, children and adults with asthma have an increased rate of vaso-occlusive pain episodes, acute chest syndrome (ACS) episodes, and premature mortality when compared with those without asthma. However, the diagnosis of asthma is challenging, particularly among children with a preexisting chronic disease that has many asthma symptoms (wheezing, coughing and shortness of breath) and clinical risk factors (elevated IgE levels, lower airway obstruction, airway hyperresponsiveness and bronchodilator response) associated with asthma.
Management of asthma in individuals with SCD should be treated in accordance with National Institutes of Health National Asthma Education and Prevention Program recommendations (http:// www.nhlbi.nih.gov/guidelines/asthma/). Unfortunately, optimal management is less clear for individuals with SCD who do not meet criteria for a diagnosis of asthma but manifest occasional or recurrent wheezing. Given the clinical overlap between symptoms of SCD (dyspnea on exertion, chest tightness, and more recently observed wheezing) and asthma, making a clear diagnosis of asthma is more complex than in the general population. The focus of this review is to summarize the basic and clinical data supporting wheezing as a harbinger for future SCDrelated morbidity.
METHODS
This review was not considered human patients research. A systematic search strategy was employed for PubMed, Ovid, and the Cochrane library databases. Search terms included 'sickle AND asthma' and 'sickle AND wheeze.' In addition to results of systematic searches, relevant citations that did not come up on the initial search, but were found in the reference sections of articles pulled from the initial search, were also included. Search results were downloaded in PDF form and reviewed individually by the lead author. Summaries of all articles were compiled into tabular format for all authors to review.
EPIDEMIOLOGY
Prevalence estimates for wheezing in SCD vary with study methodology. Retrospective cohorts typically report lower rates of wheezing [3,4,5 & ,6-8] with estimates ranging from 3.6 to 18.7%. Many of the retrospective estimates were based on specialty practices that do not reflect the full spectrum of either asthma or sickle cell disease. Higher estimates of wheezing are likely due to selection bias (some cohorts reviewed charts during episodes of ACS). Five prospective studies document the prevalence of wheezing in individuals with SCD (Table 1) . Knight-Madden et al. [9 && ,10] and Jacob et al. [11] used modified versions of the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire in separate cohorts of children with SCD and found the prevalence of wheezing to range from 29 to 41%. A separate pediatric cohort by Field et al. [12] used the American Thoracic Society Division of Lung Diseases (ATS-DLD) survey and found the prevalence of wheezing to be 51%. Participants were not selected based on the presence of asthma; however, all three participating sites had SCD programs with an extensive influence of asthma experts.
More recently, in a prospective cohort of 114 adults from St Louis with SCD, Cohen et al. [13] reported that the prevalence of recurrent severe wheezing was 64%. Of particular interest in the St Louis cohort, the prevalence of various respiratory symptoms was stratified by those who did and did not carry a physician diagnosis of asthma. Of adults who reported wheezing, only 38% carried a diagnosis of asthma. Those who carried a diagnosis of asthma were more likely to have other clinical features classically associated with atopy and asthma, including eosinophilia, elevated serum IgE, eczema, allergic rhinitis and a family history of atopy. Wheezing, especially wheezing without colds, was more likely to occur in individuals with an asthma diagnosis; however, substantial
KEY POINTS
Wheezing is common in SCD and in some individuals represents an intrinsic component of SCD-related lung disease rather than asthma.
Regardless of the cause, individuals with SCD and with recurrent wheezing are at increased risk for subsequent morbidity and premature mortality.
Individuals who acutely wheeze and have respiratory symptoms should be managed with a beta agonist and short-term treatment of oral steroids, typically less than 3 days to attenuate rebound vaso-occlusive disease.
For those who wheeze and have a history or examination associated with atopy, we consider asthma treatment and monitoring per National Heart, Lung and Blood Institute asthma guidelines.
proportions of individuals without asthma reported wheezing with exercise (30%), without colds (18%), during colds (51%) and recurrent severe wheezing (20%). These results in children and adults with SCD strongly suggest that, regardless of a diagnosis of asthma, wheezing symptoms are common [14] .
CAUSE OF WHEEZING DUE TO SICKLE CELL DISEASE
Based on preclinical and clinical findings, the cause of wheezing due to SCD appears to be inflammatory; however, the underlying factors that contribute to this inflammation are still poorly understood. Murine models of SCD lungs show several important differences in comparison to control mice [15] . Even under normoxic conditions lungs of SCD mice demonstrate higher levels of xanthine oxidase (a marker of vascular injury), nitrotyrosine [a marker of nitric oxide (NO) scavenging by reactive oxygen species] and lower cyclic guanosine monophosphate (a marker of NO biological activity) than controls [16] . In another study, lung sections of SCD mice demonstrated increased inflammatory cell counts (eosinophils) and elevated IgE levels in comparison with control mice. SCD mice were more sensitive to experimental induction of asthma with ovalbumin, and exposure to hypoxia also dramatically increased markers of vascular injury and perturbations of NO production in SCD mice in comparison with control. Taken together, these data suggest that, even under normal conditions, the lungs of SCD mice experience varying degrees of injury that may contribute to alterations in pulmonary physiology [15] .
ASSOCIATIONS BETWEEN WHEEZING AND SICKLE CELL DISEASE MORBIDITY
A physician diagnosis of asthma is well established as an important risk factor for increased SCD morbidity (pain, ACS and stroke) and premature mortality [5 & ,7,9 && , [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . The few studies that have directly addressed the effects of wheezing in SCD morbidity suggest that the adverse associations between asthma and SCD complications may be in part due to collinearity with wheezing. We propose a conceptual model whereby wheezing, a sign of severe narrowing of small airways, results in regional hypoxia within the lung, thereby limiting the lung's ability to reverse red cell sickling and promoting increased systemic complications of SCD ( Fig. 1) .
In a retrospective cohort of emergency department (ED) visits for SCD, our group demonstrated that a physician diagnosis of asthma was associated with an adjusted 44% increase in ED visits for pain [95% confidence interval (CI) 2-104%]; however, individuals who had at least one episode of wheezing documented in their medical record (at any time, not necessarily during an ED visit) had a 118% increase in ED visits for pain (95% CI 56-205%). Similar effects were observed for acute chest syndrome. A history of wheezing was associated with a 158% increase in the rate of ACS, whereas for asthma, a statistically significant increase was not found (rate ratio 1.00, 95% CI 0.41-2.47) [6].
In two prospective cohorts, a diagnosis of asthma (often considered a lifelong condition) without having active respiratory symptoms was not associated with substantial increases in SCD morbidity 
DIFFERENTIAL DIAGNOSIS OF WHEEZING IN SICKLE CELL DISEASE
In the individual with SCD who presents with new wheezing, the differential diagnosis varies with age.
In young children, one should consider recurrent viral infection, reflux, aspiration and rare causes such as congestive heart failure, tuberculosis, and even cystic fibrosis. Anatomic congenital abnormalities such as vascular ring, congenital lobar emphysema, and cystic adenomatoid malformation may present with wheeze. In older children and adolescents, vocal cord dysfunction may also cause wheezing. Depending on the geographic region, pulmonary mycoses (histoplasmosis, coccidiomycosis) can be an important cause of wheezing in children and adults. For adults, congenital anatomic causes of wheezing are largely replaced by acquired abnormalities, including malignancies and nonmalignant tumors producing airways compression. In older adults with SCD who smoke, chronic obstructive pulmonary disease is one of the most important causes of recurrent respiratory symptoms. Although these causes of wheezing are not specifically associated with SCD, they should be considered before an individual is labeled as having asthma or SCD asthma-like-syndrome.
EVALUATION OF WHEEZING IN INDIVIDUALS WITH SICKLE CELL DISEASE
The evaluation of an individual with SCD who reports, or presents with, wheezing should begin with a detailed review of exposures, exacerbating factors and other atopic diseases (eczema and rhinitis). Figure 2 provides sample respiratory questions from the National Asthma Education and Prevention Program (NAEPP) that we recommend for the identification of clinically important respiratory symptoms in SCD. A careful family history for atopic disease is also indicated. The examination should look for stigmata of atopy, including eczema, periorbital puffiness or discoloration (due to venous congestion), allergic salute (a thin horizontal line Wheezing is common in SCD and in some individuals represents an intrinsic component of SCD-related lung disease rather than asthma. Both etiologies of wheeze likely create ventilation-perfusion mismatch, which increases regional hypoxia, red cell sickling, membrane damage and inflammation, leading to increased systemic complications of SCD.
across the nose caused by frequent rubbing), tonsillar hypertrophy and respiratory findings (wheeze, increased expiratory time and cough). Our group recommends annual spirometry in all individuals with SCD. Bronchoprovocation with methacholine or cold air is not recommended as this has been associated with adverse events [29] and does not provide diagnostic value for asthma, as an overwhelming majority of patients (as high as 78% in some series) with SCD exhibit airway hyper-responsiveness [30] [31] [32] . Exhaled nitric oxide is also not recommended as part of clinical care. As sleep disordered breathing is associated with pulmonary disease and increased SCD morbidity, we recommend polysomnography for any individual with low daytime oxygen saturation or signs of obstructive sleep apnea .
Assessment of wheeze severity
To classify the severity of pulmonary symptoms we recommend the NAEPP classification system that is used for asthma symptoms (Fig. 3) . Nighttime awakenings due to cough, wheeze or chest tightness are particularly concerning and two or more episodes per month should be considered an indication to treat with controller medications (see evaluation of wheezing in individuals with sickle cell disease).
Providers should also ask about respiratory symptoms with and without exercise. For students with SCD, a question regarding whether there is wheezing or coughing associated with physical education class is important to include. Respiratory symptoms more frequent than twice per week would be classified as persistent and requiring long-term controller medication.
MANAGEMENT OF WHEEZING IN SICKLE CELL DISEASE: CHRONIC WHEEZE
For individuals with recurrent respiratory symptoms, those who meet criteria for a diagnosis of asthma should be treated in accordance with National Institutes of Health National Asthma Education and Prevention Program guidelines. Optimal management is less clear for individuals who, after a pulmonary evaluation, are not given a diagnosis of asthma, yet occasionally manifest wheezing or other symptoms. For persistent wheeze (three or more times a week on a regular basis), we recommend treatment with an asthma medicine (bronchodilator with inhaled corticosteroid or leukotriene receptor antagonist) and then follow up to determine the usefulness. For wheeze with exercise, we recommend pretreatment 20 min before exercise with bronchodilator and follow-up with a history from
In the past 12 months ...
In the past 4 weeks, have you had coughing, wheezing, or shortness of breath ...
¡ Have you had a sudden severe episode or recurrent episodes of coughing, wheezing (high-pitched whistling sounds when breathing out), chest tightness, or shortness of breath?
¡ Have you had colds that 'go to the chest' or take more than 10 days to get over?
¡ Have you had coughing, wheezing, or shortness of breath during a particular season or time of the year?
¡ Have you had coughing, wheezing, or shortness of breath in certain places or when exposed to certain things (e.g., animals, tobacco smoke, perfumes)?
¡ Have you used any medications that help you breathe better? How often? the patient, parent or physical education teacher to determine usefulness. If neither approach is useful for the symptoms, we recommend a careful re-evaluation to determine the cause of symptoms (with special consideration of rare causes and pulmonary mycoses) as well as making sure that the treatments were used thoroughly and correctly. The recommendations in this section are based upon expert opinion. There are no studies available regarding the use of inhaled steroids or leukotriene ¡ For population-based evaluations, clinical research, or characterization of a patient's overall asthma severity after control is achieved.
For cli.nical management, the focus is on monitoring the level of control (See figure 3-5b.) , not the level of severity, once treatment is established. Step 2
Step 3 or 4
Step 5 or 6 Step 1
Classification of asthma severity
Lowest level of treatment required to maintain control (see figure 4-1b for treatment steps.)
Mild Moderate

Persistent Intermittent
Severe FIGURE 3. National Asthma Education and Prevention Program (NAEPP) schema for classification of asthma severity. We recommend using the NAEPP schema to classify the severity of symptoms in individuals with sickle cell disease (SCD) who report wheezing cough or shortness of breath regardless of whether or not the patient carries a diagnosis of asthma. The severity of symptoms then dictates the level of treatment, which is described in Figure 4 . Adapted from the NAEPP 2007 guidelines (http://www.nhlbi.nih.gov/guidelines/asthma/). receptor antagonists in SCD. There is also a dearth of evidence to guide use of bronchodilators in SCD. Cochrane reviews by Knight-Madden et al. [57, 58] have not identified a single article regarding albuterol and SCD.
MANAGEMENT OF ACUTE EPISODES OF WHEEZING
For acute wheezing episodes we recommend administration of an inhaled beta agonist in all cases. We cautiously use systemic glucocorticoids for very short courses of 1-2 days (initial dose 2 mg/kg) as there are associations with rebound pain [58] [59] [60] [61] [62] [63] , fat necrosis [64] , and intracranial hemorrhage [65] . Below are recommendations for management of acute wheezing in commonly encountered situations:
(1) Wheezing in the setting of acute chest syndrome with a prior diagnosis of asthma: we recommend bronchodilator and short course steroids (single dose dexamethasone 0.3-0.6 mg/kgmax 10 mg or short course prednisone/prednisolone 2 mg/kg-max 60 mg for up to 3 days). (2) Wheezing in the setting of acute chest syndrome without a prior diagnosis of asthma: perform a careful history for atopic disease that would suggest undiagnosed asthma (if there is high suspicion for asthma, follow recommendations above). If there is low suspicion for asthma, we recommend bronchodilators and a single dose of prednisone/prednisolone (2 mg/kg-max 60 mg) with a re-evaluation daily for the need to continue steroids. (3) Acute wheezing without acute chest syndrome with a prior diagnosis of asthma: we recommend bronchodilator administration with a short course of steroids (single dose dexamethasone 0.3-0.6 mg/kg-max 10 mg or short course prednisone/prednisolone 2 mg/kg-max 60 mg for up to 3 days) for individuals who do not immediately improve with bronchodilators. For individuals who are not taking an asthma controller medication, we strongly consider initiating treatment at that time (inhaled corticosteroid or leukotriene receptor antagonist). We favor single dose prednisone/prednisolone over dexamethasone for milder cases of wheezing as we have not experienced any rebound pain or noticeable adverse events with single dose prednisone. (4) Acute wheezing without acute chest syndrome and without a prior diagnosis of asthma: Perform a careful history for atopic disease that would suggest undiagnosed asthma, (if there is high suspicion for asthma follow recommendations above). If there is low suspicion for asthma, we recommend bronchodilators plus a single dose of prednisone/prednisolone (2 mg/kg-max 60 mg) with a re-evaluation daily for the need to continue steroids. The patient should be discharged with a prescription for bronchodilator.
WHEN TO REFER TO AN ASTHMA SPECIALIST
We recommend referral to an asthma specialist in any situation in which the patient exhibits recurrent pulmonary symptoms (wheeze, cough, chest tightness, even dyspnea on exertion), multiple ACS episodes or a single ACS episode that requires intubation. Referral to an asthma specialist is also recommended for individuals who carry a diagnosis of asthma and their symptoms are not easily controlled with standard controller medicines (inhaled corticosteroids at low or medium dose, oral leukotriene receptor antagonists). Patients who require high dose inhaled steroids or long acting beta agonist combination medications (NAEPP treatment level 3 or greater - Fig. 4 ) should be referred for pulmonary evaluation. Depending on location, it may be difficult to find an asthma specialist who has experience with SCD. Asthma specialists who do not have prior experience with SCD are usually sufficient, as the goals of care are the same (to progressively step up asthma therapy until symptoms are adequately controlled). In this situation, it is important to communicate to the asthma specialist that, while definitive evidence is lacking, because of the excellent safety profile of most asthma control medications, providers should not withhold asthma treatments for fear of exacerbating SCD.
CONCLUSION
Wheezing is common in SCD and in some individuals represents an intrinsic component of SCD-related lung disease rather than asthma. Regardless of the cause, individuals with SCD and with recurrent wheezing are at increased risk for subsequent morbidity and premature mortality. We believe individuals who acutely wheeze and have respiratory symptoms should be managed with a beta agonist and short-term treatment of oral steroids, typically less than 3 days to attenuate rebound vaso-occlusive disease. For those who wheeze and have a history or examination associated with atopy, we consider asthma treatment and monitoring per National Heart, Lung and Blood Institute asthma guidelines. Prospective SCD-specific clinical trials will be necessary to address whether anti-inflammatory asthma therapies (leukotriene antagonists, inhaled corticosteroids) can safely mitigate the sequelae of wheezing in SCD.
Acknowledgements
None.
Conflicts of interest
There are no conflicts of interest.
¡ The stepwise approach is meant to assist, not replace, the clinical decisionmaking required to meet individual patient needs. ¡ If alternative treatment is used and response is inadequate, discontinue it and use the preferred treatment before stepping up. ¡ Zileuton is a less desirable alternative due to limited studies as adjunctive therapy and the need to monitor liver function. Theophylline requires monitoring of serum concentration levels. ¡ In step 6, before oral systemic corticosteroids are introduced, a trial of high-dose ICS + LABA + either L TRA, theophylline, or zileuton may be considered, although this approach has not been studied in clinical trials. ¡ Step 1, 2, and 3 preferred therapies are based on Evidence A; step 3 alternative therapy is based on Evidence A for L TRA, Evidence B for theophylline, and Evidence D for zileuton.
Step 4 preferred therapy is based on Evidence B, and alternative therapy is based on Evidence B for L TRA and theophylline and Evidence D for zileuton.
Step 5 preferred therapy is based on Evidence B.
Step 6 preferred therapy is based on (EPR-2 1997) and Evidence B for omalizumab ¡ Immunotherapy for steps 2-4 is based on Evidence B for house-dust mites, animal danders, and pollens; evidence is weak or lacking for molds and cockroaches. Evidence is strongest for immunotherapy with single allergens. The role of allergy in asthma is greater in children than in adults. ¡ Clinicians who administer immunotherapy or omalizumab should be prepared and equipped to identify and treat anaphylaxis that may occur.
__ Key: Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy. EIB, exercise-induced bronchospasm; ICS, inhaled corticosteroid; LABA, long-acting inhaled beta 2agonist; L TRA, leukotriene receptor antagonist; SABA, inhaled short-acting beta 2 
-agonist
Step Step 6
Quick-relief medication for all patients • SABA as needed for symptoms. Intensily of treatment depends on severity of symptoms: up to 3 treatments at 20-minute intervals as needed. Short course of oral systemic corticosteroids may be needed. • Use of SABA >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and the need to step up trealment.
Persistent asthma: daily medication Consult with asthma specialist if step 4 care or higher is required.
Consider consultation at step 3.
Intermittent Asthma
Each step: Patient education, environmental control, and management of comorbidities.
Steps 2-4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma (see notes).
Step up if needed (first check adherence. environmental control, and comorbid conditions)
Assess control
Step down if possible (and asthma is well controlled at least 3 months) Notes: 
